Press release
Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Algorithm, Pipeline Analysis | IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode
Melanoma Pipeline Insight
Melanoma Pipeline constitutes 150+ key companies continuously working towards developing 170+ Melanoma treatment therapies, analyzes DelveInsight.
Melanoma Overview:
Melanoma is a form of cancer that begins in melanocytes, the cells responsible for producing pigment. While approximately 90% of melanomas arise in the skin, the disease can also occur in the eyes, internal organs, and mucous membranes of the gastrointestinal, respiratory, and urogenital systems. It is the third most prevalent skin cancer after basal cell carcinoma and squamous cell carcinoma and ranks as the fifth most common cancer in men and sixth in women. Although widespread, melanoma has traditionally been challenging to treat, with slower drug development progress compared to other cancers.
Melanoma often spreads to the lymph nodes, lungs, liver, bones, and brain. Warning signs include abnormal skin growths, changes in existing moles-such as size increase, darkening, irregular borders, or color changes-sores that don't heal, and skin lesions that become painful, itchy, or sensitive. Diagnosis generally begins with a visual skin assessment and the ABCDE method (asymmetry, border, color, diameter, and evolution). If melanoma is suspected, a biopsy is conducted-either a punch, excisional, or shave biopsy-to analyze the tissue. Tumor thickness is examined under a microscope, as thicker tumors have a higher chance of spreading. Further tests, including imaging (CT, MRI, PET scans) and bloodwork (such as lactate dehydrogenase levels), are used to check for metastasis.
Treatment is tailored based on the stage of melanoma and the patient's overall health. In early stages, surgery may be curative. For more advanced cases, lymph node dissection may be required to limit further spread, and metastasectomy can remove small tumor deposits in organs. Additional treatments include targeted therapies that focus on specific cancer cells, radiation, and immunotherapy-which is widely pursued by biopharmaceutical companies to boost the immune system's ability to combat melanoma.
Request for a detailed insights report on Melanoma pipeline insights [https://www.delveinsight.com/report-store/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
"Melanoma Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Melanoma Therapeutics Market.
Key Takeaways from the Melanoma Pipeline Report
*
DelveInsight's Melanoma pipeline report depicts a robust space with 150+ active players working to develop 170+ pipeline therapies for Melanoma treatment.
*
Key Melanoma companies such as IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode Therapeutics, Achilles Therapeutics UK Limited, Evaxion Biotech, InxMed, AiVita Biomedical, Cytovation AS, Ono Pharmaceuticals, Neon Therapeutics, Iovance Biotherapeutics, and others are evaluating new drugs for Melanoma to improve the treatment landscape.
*
Promising Melanoma pipeline therapies in various stages of development include IO102 IO103, mRNA 4157, MK-4830, BNT111, TILT 123, and others.
Recent breakthroughs in the Melanoma Pipeline Segment:
*
January 2025 - Ultimovacs ASA: A randomized, open-label study is being conducted to evaluate the efficacy and safety of UV1 vaccination in combination with nivolumab and ipilimumab as a first-line treatment for adult patients with histologically confirmed unresectable metastatic melanoma.
*
January 2025 - Regeneron Pharmaceuticals: This study is investigating the experimental drug fianlimab (REGN3767) in combination with cemiplimab (REGN2810), referred to as the "study drugs." The research focuses on melanoma patients and aims to assess the safety and effectiveness of fianlimab and cemiplimab compared to the approved combination of relatlimab and nivolumab, marketed as Opdualag Trademark , for treating melanoma in both adults and children.
*
January 2025 - Amgen: This study aims to evaluate the efficacy, safety, and immunogenicity of ABP 206 in comparison with nivolumab in patients with treatment-naive, unresectable, or metastatic melanoma. Participants will be randomly assigned (1:1) to receive either ABP 206 or nivolumab and will continue treatment until disease progression, unacceptable toxicity, or withdrawal of consent, for a maximum of 24 months. The total study duration for each participant is approximately 26 months.
*
In April 2024, Obsidian Therapeutics shared an update on its Phase I first-in-human trial of OBX-115 tumor-infiltrating lymphocyte (TIL) cell therapy for patients with advanced or metastatic melanoma. The update, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, included safety data with a median follow-up of 25 weeks and newly detailed efficacy results.
*
In April 2024, Iovance Biotherapeutics announced that clinical data for lifileucel combined with pembrolizumab in frontline advanced melanoma, along with translational data, would be featured at the 2024 ASCO Annual Meeting.
Melanoma Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Melanoma Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Melanoma treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Melanoma market.
Download our free sample page report on Melanoma pipeline insights [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Melanoma Emerging Drugs
*
IO102 IO103 : IO Biotech
*
mRNA 4157: Moderna Inc.
*
MK-4830: Merck Sharp & Dohme LLC
*
BNT111: BioNTech SE
*
TILT 123: TILT Biotherapeutics LLC
Melanoma Companies
Around 150 key companies are actively developing therapies for colorectal cancer. Among them, IO Biotech has a melanoma drug candidate in the most advanced stage of development, specifically Phase III clinical trials.
DelveInsight's report covers around 170+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Melanoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Melanoma Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Melanoma Therapies and Key Companies: Melanoma Clinical Trials and advancements [https://www.delveinsight.com/report-store/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Melanoma Pipeline Therapeutic Assessment
- Melanoma Assessment by Product Type
- Melanoma By Stage
- Melanoma Assessment by Route of Administration
- Melanoma Assessment by Molecule Type
Download Melanoma Sample report to know in detail about the Melanoma treatment market @ Melanoma Therapeutic Assessment [https://www.delveinsight.com/sample-request/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Melanoma Current Treatment Patterns
4. Melanoma - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Melanoma Late-Stage Products (Phase-III)
7. Melanoma Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Melanoma Discontinued Products
13. Melanoma Product Profiles
14. Melanoma Key Companies
15. Melanoma Key Products
16. Dormant and Discontinued Products
17. Melanoma Unmet Needs
18. Melanoma Future Perspectives
19. Melanoma Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Melanoma Pipeline Reports Offerings [https://www.delveinsight.com/report-store/melanoma-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=melanoma-clinical-trials-companies-therapeutic-assessment-therapies-algorithm-pipeline-analysis-io-biotech-moderna-inc-merck-sharp-dohme-llc-biontech-se-tilt-biotherapeutics-llc-nykode]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Melanoma Clinical Trials, Companies, Therapeutic Assessment, Therapies, Algorithm, Pipeline Analysis | IO Biotech, Moderna Inc., Merck Sharp & Dohme LLC, BioNTech SE, TILT Biotherapeutics LLC, Nykode here
News-ID: 4115042 • Views: …
More Releases from ABNewswire
Denver's Best Appliance Repair Responds to Rising Demand for Emergency Appliance …
Denver's Best Appliance Repair expands emergency services across the Denver metro with same-day repairs, 7-day availability, 5-year parts warranty, and professional licensed technicians serving residential and commercial clients.
Household appliance failures don't follow a schedule. When a refrigerator stops cooling in the middle of summer or a washing machine floods a basement on a Sunday evening, families need immediate help. Denver's Best Appliance Repair has responded to this growing need by…
Oak Hill Clinic Reaches 30,000 Client Milestone with Results-Driven Deep Tissue …
Deep Relief in Oak Hill, Austin, has served 30,000 clients through specialized massage, chiropractic, and acupuncture care. The clinic accepts insurance and focuses on results-driven treatments for pain relief.
Deep Relief, an Oak Hill-based wellness clinic, has achieved a significant milestone by serving more than 30,000 clients seeking Relief from chronic pain, muscle tension, and mobility issues. The clinic's success stems from its commitment to advanced, results-focused bodywork that goes beyond…
Vertex Fleet Expands Nationwide Network to Combat Growing Trailer Drop Yard Shor …
Vertex Fleet announces major expansion of secure parking facilities nationwide, addressing the critical shortage of commercial vehicle storage with 15+ new locations featuring 24/7 security and technology-driven access.
The freight and logistics industry faces a mounting crisis as demand for secure parking spaces continues to outpace supply across the United States. Vertex Fleet [https://www.vertexfleet.com/], a leading provider of industrial outdoor storage solutions, has announced significant expansion plans to address this critical…
HVAC in Denver Sees Service Enhancement as Denver's Best Heating and AC Repair L …
Denver's Best Heating and AC Repair expands 24/7 emergency services across 23 metro cities, offering A+ rated heating, cooling, and commercial HVAC solutions with rapid response times and multi-brand expertise.
Denver's Best Heating and AC Repair [https://www.denversbestheatingandacrepair.com/]has expanded its service capabilities to meet growing demand for reliable heating and cooling solutions across the Denver Metro area. The A+ rated contractor now provides 24/7 emergency response services to 23 cities, addressing critical…
More Releases for Melanoma
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
The Metastatic Melanoma Therapeutics Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Expected Metastatic Melanoma Therapeutics Market Size During the Forecast Period?
The market size for therapeutics in metastatic melanoma has swiftly increased in the past few years. It is projected to augment…
Rising Incidence Of Melanoma Cases Boosts Metastatic Melanoma Therapeutics Marke …
What combination of drivers is leading to accelerated growth in the metastatic melanoma therapeutics market?
The growth of the metastatic melanoma therapeutics market is anticipated to be fueled by the increasing prevalence of melanoma cases. Melanoma, a type of skin cancer, originates in the cells, known as melanocytes, that determine the skin's pigment. Melanomas can develop on any part of the skin. Metastatic melanoma therapeutics comprise various treatments designed to interrupt…
Key Influencer in the Melanoma Therapeutics Market 2025: Surge In Melanoma Incid …
How Are the key drivers contributing to the expansion of the melanoma therapeutics market?
The rise in melanoma cases is predicted to fuel the expansion of the melanoma therapeutics market. Melanoma, a type of skin cancer, begins in the melanocytes. The therapies and medications used to treat melanoma patients and mitigate the effects of cancer are known as melanoma therapeutics. An increase in melanoma cases, therefore, leads to a surge in…
Skin Cancer Market By Cancer Type (Melanoma, Non-melanoma)
Most skin cancers are locally destructive malignant growth of the skin. They come from the epidermis cells, the skin's superficial layer. The vast majority of these types of skin cancers seldom spread (metastasize) to other areas of the body and become life-threatening, unlike cutaneous malignant melanoma.
Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00018117/?utm_source=OpenPR&utm_medium=10379
Key Players Analysis:
• Pfizer Inc.
• Bristol-Myers Squibb Company
• Abbott Laboratories
• Amgen, Inc.
• Merck & Co., Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Sanofi S.A.
• Qiagen NV
• Sun Pharmaceutical Industries Ltd…
Melanoma Diagnostics Market - Shining Light on Melanoma: Transforming Lives with …
Newark, New Castle, USA - new report, titled Melanoma Diagnostics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Melanoma Diagnostics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Melanoma Diagnostics market. The report offers an overview of the market, which…
Intraocular Melanoma Treatment Market Drivers
Neurological disorder diagnostics tools are medical devices, which are used in diagnosis of various neurological disorders such as Alzheimer’s disease (AD), Parkinson’s disease (PD), and Multiple Sclerosis. The devices which are majorly used in diagnosis are imaging tools such as Computed Tomography (CT), Magnetic Resonance Imaging (MRI), and in-vitro diagnostics tools such as biomarker and biopsy. Increasing prevalence of neurological disorders in the recent past has increased demand for diagnostic…
